Literature DB >> 15884764

Decreased serum adiponectin in adolescents and young adults with familial primary hypercholesterolemia.

Lian-Yu Lin1, Chiau-Suong Liau, Wei-Shiung Yang, Ta-Chen Su.   

Abstract

Decreased serum adiponectin is associated with dyslipidemia. However, serum adiponectin status has never before been studied in patients with familial-related severe primary hypercholesterolemia (FRSPH). The aim of this study is to measure serum adiponectin level in a group of young patients with FRSPH and determine its correlation with insulin-resistant status. Twenty-three patients with FRSPH [average LDL-cholesterol (LDL-C) = 250.8 (190-610) mg/dL] without clinical manifestations of metabolic syndrome as well as 46 healthy (control) adolescents and young adults (<30 yr old) were included. The serum adiponectin, fasting sugar, insulin, lipids, systolic and diastolic blood pressure (SBP and DBP), and anthropometrical indices such as body mass index and waist circumference were obtained. The homeostasis model assessment (HOMA) was calculated to estimate the insulin resistant status. Compared with healthy controls, patients with FRSPH had a significantly lower mean serum adiponectin level (7.7+/-1.8 microg/mL vs. 10.1+/-4.3 microg/mL, P= 0.013). After adjustment for HOMA and associated covariates, multiple linear regression analysis showed that patients with FRSPH are significantly associated with hypoadiponectinemia. Compared with healthy controls, patients with FRSPH had a significantly lower mean serum adiponectin level (7.7 +/-1.8 microg/mL vs. 10.1+/-4.3 microg/mL, P = 0.013). After adjustment for HOMA and associated covariates, multiple linear regression analysis showed that patients with FRSPH are significantly associated with hypoadiponectinemia. The serum adiponectin levels are lower in young patients with FRSPH without clinical manifestations of metabolic syndrome. The mechanism of hypoadiponectinemia in patients with FRSPH is probably independent of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15884764     DOI: 10.1007/s11745-005-1371-7

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  30 in total

1.  Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia.

Authors:  T Sampietro; M Tuoni; M Ferdeghini; A Ciardi; P Marraccini; C Prontera; G Sassi; M Taddei; A Bionda
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

2.  An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls.

Authors:  Y Okamoto; Y Arita; M Nishida; M Muraguchi; N Ouchi; M Takahashi; T Igura; Y Inui; S Kihara; T Nakamura; S Yamashita; J Miyagawa; T Funahashi; Y Matsuzawa
Journal:  Horm Metab Res       Date:  2000-02       Impact factor: 2.936

3.  Hyperlipidaemias and serum cytokines in patients with coronary artery disease.

Authors:  Katarzyna Mizia-Stec; Barbara Zahorska-Markiewicz; Tadeusz Mandecki; Joanna Janowska; Andrzej Szulc; Ewa Jastrzekbska-Maj; Zbigniew Gasior
Journal:  Acta Cardiol       Date:  2003-02       Impact factor: 1.718

4.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

5.  Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia.

Authors:  F J Raal; V R Panz; G J Pilcher; B I Joffe
Journal:  J Intern Med       Date:  1999-07       Impact factor: 8.989

6.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

Authors:  K Hotta; T Funahashi; Y Arita; M Takahashi; M Matsuda; Y Okamoto; H Iwahashi; H Kuriyama; N Ouchi; K Maeda; M Nishida; S Kihara; N Sakai; T Nakajima; K Hasegawa; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Hanafusa; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-06       Impact factor: 8.311

7.  Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Yoshihisa Okamoto; Shinji Kihara; Noriyuki Ouchi; Makoto Nishida; Yukio Arita; Masahiro Kumada; Koji Ohashi; Naohiko Sakai; Iichiro Shimomura; Hideki Kobayashi; Naoki Terasaka; Toshimori Inaba; Tohru Funahashi; Yuji Matsuzawa
Journal:  Circulation       Date:  2002-11-26       Impact factor: 29.690

8.  Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels.

Authors:  Aina S Lihn; Bjørn Richelsen; Steen B Pedersen; Steen B Haugaard; Gulla Søby Rathje; Sten Madsbad; Ove Andersen
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-07-22       Impact factor: 4.310

9.  Decreased plasma adiponectin concentrations in women with dyslipidemia.

Authors:  Miyao Matsubara; Shoji Maruoka; Shinji Katayose
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

10.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice.

Authors:  J Fruebis; T S Tsao; S Javorschi; D Ebbets-Reed; M R Erickson; F T Yen; B E Bihain; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  2 in total

1.  Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes.

Authors:  C-H Chu; J-K Lee; H-C Lam; C-C Lu; C-C Sun; M-C Wang; M J Chuang; M-C Wei
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

2.  Primary hypercholesterolemia, carotid atherosclerosis and insulin resistance among Chinese.

Authors:  Kuo-Liong Chien; Chiau-Suong Liau; Ming-Fong Chen; Yuan-Teh Lee; Jiann-Shing Jeng; Bao-Show Hwang; Ta-Chen Su
Journal:  Lipids       Date:  2007-12-15       Impact factor: 1.880

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.